Noopur S. Raje, MD, discusses the design of the randomized phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.
Noopur S. Raje, MD, professor of medicine at Harvard Medical School and director of the Multiple Myeloma Program at Massachusetts General Hospital, discusses the design of the randomized phase 3 ENDURANCE (E1A11) trial in newly diagnosed multiple myeloma.
At the 2020 ASCO Virtual Scientific Program, findings from the study showed that carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) did not significantly improve progression-free survival compared with bortezomib (Velcade), lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma who were not intended for up-front autologous stem cell transplant.
The trial randomized patients to receive KRd (n = 545) versus VRd (n = 542), says Raje. Notably, these are 2 of the most commonly used induction regimens in this space, Raje concludes.